Shire news from FierceBiotech
NewsShire to buy Jerini in $521M deal
With an eye toward snapping up a late-stage orphan drug for hereditary angiodema - a rare genetic disease -- Shire has agreed to pay $521 million to acquire Berlin-based Jerini AG. That's a whopping... Read more...
Mixed data for Renovo's scarring therapy
Renovo's Juvista produced a mixed set of data in two mid-stage trials. The drug produced positive data in reducing scarring but failed to demonstrate efficacy during a breast augmentation trial.... Read more...
Shire, Amicus forge $440M pact
Amicus Therapeutics has scored a $50 million upfront payment from Shire's human genetics sub for rights outside the U.S. to three experimental therapies for genetic disorders: Amigal (migalastat... Read more...
ALSO NOTED: Big CEO turnover at Big Pharma; New company takes on RNAi field; Shire hunts for buyouts; and much more...
> Turnover at the top of Big Pharma has been running at an unprecedented pace. And now, with fresh faces at the helm at nine of the world's top 12 pharma companies, there's a new generation... Read more...
3. Shire and Renovo
Who: Shire With: Renovo What: $875 million Summary: Shire forked over $75 million up front along with a $50 million equity payment to Renovo as part of an $875 million deal for the exclusive... Read more...
Shire to Massachusetts: Pass incentive bill now
The Massachusetts Legislature is taking its sweet time passing Governor Deval Patrick's proposed $1 billion incentive bill, and... Read more...
ALSO NOTED: Avandia gets Black Box Warning; Shire licensing deal complete; Pittsburgh companies gain financing; and much more..
> Hang the black crepe: the FDA has ordered new "black box" warning labels for Avandia and its Japanese cousin Actos.
Noven garners $25M payday on sales milestone
Noven will pocket the second of three potential $25 million milestones outlined in its deal with Shire. Shire says that the ADHD drug Daytrana continues to rack up enough market share to trigger the... Read more...
ALSO NOTED: CRO market hits $14B; Merck ends BioXell pact; and much more...
> Merck has ended its collaboration with BioXell on its sepsis drug TREM-1. BioXell says it will seek another company with which to partner on the drug. Report > Shire... Read more...
Progeria trial underscores challenge of rare diseasesThe mother of a young boy with Progeria has paved the way to the world's first clinical trial into a potential treatment of the disease, which will require recruiting more than half of the 42 known patients in the world. The case underscores both the promise of new genetic research into potential treatments as well as the challenges researchers face in studying rare diseases. Progeria affects only one in every four million to eight million children, most of whom die from a stroke or heart … ... Read more... | Press ReleasesShire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA (mesalamine) and AsacolShire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA(R) (mesalamine) and Asacol(R) PHILADELPHIA, Oct. 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP; Read more >> PRESS RELEASE: Amicus Therapeutics, Inc. and Shire Pharmaceuticals Group Enter Into $440 Million ex-US Licensing Agreement Amicus Therapeutics and Shire Pharmaceuticals Group Enter Into $440 Million ex-US Licensing Agreement CRANBURY, N.J., Nov. 8 -- Amicus Therapeutics, Inc. announced today that it has entered into a Read more >> PRESS RELEASE: Shire Pharmaceuticals Group's Fosrenol Does Not Meet Main Goal of Trial Shire Pharmaceuticals Group's Fosrenol Does Not Meet Main Goal of Trial PHILADELPHIA and BASINGSTOKE, England, November 6 -- Shire plc today announced the results of a Phase II study indicating that Read more >> PRESS RELEASE: Shire Voluntarily Withdraws a Limited Portion of Daytrana (Methylphenidate Transdermal System) Patches Shire Voluntarily Withdraws a Limited Portion of Daytrana (Methylphenidate Transdermal System) Patches Patches that are easier to use are available for patients and their families PHILADELPHIA, Read more >> |
Get more Shire coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
